BELLEVILLE, ON,
April 14, 2014 /PRNewswire/ -
Bioniche Life Sciences Inc. (TSX: BNC) today announced that its
shareholders have voted in favour of the sale of the Company's
Animal Health business to Vétoquinol SA.
At a Special Meeting of Shareholders held this
morning in Toronto, 39.4% of the
issued and outstanding shares were voted, with 97.4% of those
voting in favour of the sale transaction.
The transaction is expected to close
tomorrow.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and
innovative therapies for the global human health market. The
Company's primary goal is to develop and commercialize products
that advance human health and increase shareholder value. For more
information, please visit www.Bioniche.com.
Except for historical information, this news
release may contain forward-looking statements that reflect the
Company's current expectation regarding future events. These
forward-looking statements involve risk and uncertainties, which
may cause, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties
related to the regulatory approval process, and other risks
detailed from time to time in the Company's ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.